Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

Not Applicable

Not yet recruiting

• Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
• Interventions: Drug: MT1013; Drug: Cinacalcet

• Registration Number: NCT07122401
• Lead Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Brief Summary

MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active control cinacalcet in secondary hyperparathyroidism patients on maintenance dialysis. Subjects will be 1:1 randomized to receive MT1013 or cinacalcet for 26 weeks. Evaluations of iPTH, Ca, P, BMD, and biomarkers will be done across the study period, to compare efficacy and safety of MT1013 to cinacalcet.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-08
• Study First Submitted: 2025-08-01
• Study First Submitted QC: 2025-08-12
• Last Update Submitted: 2025-08-12
• Study First Posted: 2025-08-14
• Last Update Posted: 2025-08-14
• Study Start: 2025-09-30
• Primary Completion: 2026-11-26
• Study Completion: 2026-11-26

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 424

Inclusion Criteria

1. Participants capable of understanding written information ,willing to participate in, and provide a written informed consent;
2. Male or female, at least 18 years old, 18 kg/m^2 ≤BMI≤35 kg/m^2;
3. Receiving regular maintenance dialysis 3 times a week for at least 12 weeks prior to screening；
4. Dialysate calcium concentration≥1.25 mmol/L (2.5 mEq/L);
5. Subjects must have a confirmed diagnosis of Secondary Hyperparathyroidism (SHPT), with a mean pre-dialysis serum intact parathyroid hormone (iPTH) level ≥ 400 pg/mL (42.4 pmol/L), based on measurements from two non-consecutive days before dialysis, within 14 days prior to randomization;
6. Within 14 days prior to randomization, subjects must have serum calcium levels (measured pre-dialysis, or corrected serum calcium if albumin <40 g/L) ≥ 8.4 mg/dL (2.1 mmol/L) on two non-consecutive pre-dialysis measurements.

Exclusion Criteria

1. Underwent parathyroidectomy within 6 months prior to screening, or anticipated parathyroidectomy, ablation or radiation during the study;
2. Gastrointestinal bleeding or peptic ulcer medical history within 6 months prior to screening;
3. New York Heart Association (NYHA) Class III or IV heart failure within 3 months prior to screening; Symptomatic arrhythmia within 6 months prior to screening; History of torsades de pointes (TdP).
4. QTcF interval >470 ms in males or >480 ms in females on screening ECG, or other clinically significant ECG abnormalities as determined by the Investigator (e.g., third-degree atrioventricular block, sick sinus syndrome, multifocal frequent ventricular premature contractions, ventricular tachycardia, atrial fibrillation, etc.).
5. Subjects with severe uncontrolled hypertension during the screening period are excluded, defined as systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg despite optimal medical therapy prior to enrollment (excluding transient blood pressure abnormalities during dialysis).
6. History of seizure within 1 year prior to screening, or currently receiving treatment for seizure disorders;
7. Received oral cinacalcet or ivocalcet within 14 days prior to screening, or received Etelcalcetide injection treatment within 4 months prior to screening;
8. Any other condition that, in the Investigator's judgment, would make the subject unsuitable for participation in this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
MT1013	MT1013	MT1013 is administered intravenously (IV) for 26 weeks; Dummy cinacalcet will be administered orally for 26 weeks.
Cinacalcet	Cinacalcet	Cinacalcet is administered orally for 26 weeks. Dummy MT1013 is administered intravenously (IV) for 26 weeks.

Primary Outcome Measures

Name	Time	Method
Percentage of participants with > 50% reduction from baseline in mean intact parathyroid (iPTH)	EAP（Week 22-27）
Percentage of participants with > 30% reduction from baseline in mean iPTH	EAP（Week 22-27）

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Bone Mineral Density	Week 27
Change from baseline in serum calcium	EAP（Week 22-27）
Change From Baseline in serum phosphorus	EAP（Week 22-27）
Safety and Tolerance	Up to Week 30	Incidence and severity of TEAE/TESAE

Trial Locations

Locations (1)

Zhongshan Hospital; 🇨🇳 Shanghai, Shanghai, China